




Belgian Cancer Registry

CANCER FACT SHEET 2024

CERVICAL CANCER

ICD-10 C53



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

HPV: Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of cervical cancers.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Cervical cancer incidence: by region	5
1.1.1. Cervical cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024	5
1.2. Cervical cancer incidence: by tumour stage	6
1.2.1. Cervical cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	6
1.2.2. Cervical cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	6
1.2.3. Cervical cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	7
1.2.4. Cervical cancer incidence by Human Papillomavirus infection: number of new diagnoses, crude and age-standardised incidence rates, 2024	7
2. CANCER INCIDENCE TRENDS	8
2.1. Cervical cancer incidence trends: by region	8
2.1.1. Cervical cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024	8
2.2. Cervical cancer incidence trends: by tumour stage	9
2.2.1. Cervical cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards	9
2.3. Cervical cancer incidence trends: by age group	10
2.3.1. Cervical cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024	10
3. CANCER PREVALENCE	11
3.1. Cervical cancer prevalence: by region	11
3.1.1. Cervical cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024	11
4. CANCER SURVIVAL	12
4.1. Cervical cancer survival: by region	12
4.1.1. Cervical cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024	12
4.2. Cervical cancer survival: by tumour stage	14
4.2.1. Cervical cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2015-2024	14
4.2.2. Cervical cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2015-2024	15
4.2.3. Cervical cancer survival by stage: number at risk and net survival probabilities, 2015-2024	16
5. CANCER SURVIVAL TRENDS	17
5.1. Cervical cancer survival trends: by tumour stage	17
5.1.1. Cervical cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024	17
6. CANCER MORTALITY	19

6.1. Cervical cancer mortality: by region	19
6.1.1. Cervical cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023.....	19
7. CANCER MORTALITY TRENDS.....	20
7.1. Cervical cancer mortality trends: by region	20
7.1.1. Cervical cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023.....	20
8. CARCINOMA IN SITU INCIDENCE	21
8.1. Cervical carcinoma in situ incidence: by region	21
8.1.1. Cervical carcinoma in situ incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024.....	21
9. CARCINOMA IN SITU INCIDENCE TRENDS.....	22
9.1. Cervical carcinoma in situ incidence trends: by region.....	22
9.1.1. Cervical carcinoma in situ incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	22
9.2. Cervical carcinoma in situ incidence trends: by age group	24
9.2.1. Cervical carcinoma in situ incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	24

1. CANCER INCIDENCE



1.1. Cervical cancer incidence: by region

1.1.1. *Cervical cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024*

N [CR]																						ESR2013 (95%CI)	
Region	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages		
Females																							
Belgium	0	0	0	0	0	5	29	55	78	70	65	68	62	59	50	30	20	20	7	3	621	10.4	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[7.4]	[14.3]	[20.2]	[18.9]	[16.9]	[17.3]	[16.1]	[17.1]	[16.7]	[11.7]	[11.5]	[14.8]	[9.7]	[13.9]	[10.4]	(9.6; 11.3)	
Brussels	0	0	0	0	0	1	3	2	7	1	3	7	6	2	5	2	3	1	0	0	43	7.8	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[5.5]	[4.1]	[15.4]	[2.4]	[7.8]	[20.3]	[19.6]	[8.0]	[23.2]	[10.8]	[23.4]	[10.4]	[0.0]	[0.0]	[6.7]	(5.4; 10.2)	
Flanders	0	0	0	0	0	3	15	35	36	34	37	36	35	31	28	15	12	16	7	2	342	9.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.5]	[6.9]	[16.3]	[16.2]	[16.1]	[16.7]	[15.4]	[15.1]	[15.0]	[15.8]	[9.7]	[10.9]	[18.4]	[15.5]	[15.5]	[9.9]	(8.7; 10.8)	
Wallonia	0	0	0	0	0	1	11	18	35	35	25	25	21	26	17	13	5	3	0	1	236	12.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[9.3]	[15.0]	[29.6]	[29.9]	[19.9]	[20.0]	[17.0]	[23.0]	[17.0]	[15.7]	[9.7]	[7.7]	[0.0]	[15.1]	[12.5]	(11.1; 14.3)	

1.2. Cervical cancer incidence: by tumour stage

1.2.1. Cervical cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages 0+	
I	93 [4.9]	51 [4.4]	37 [2.8]	181 [3.0]	3.1 (2.6; 3.5)
II	23 [1.2]	30 [2.6]	33 [2.5]	86 [1.4]	1.4 (1.1; 1.7)
III	33 [1.7]	43 [3.7]	47 [3.6]	123 [2.1]	2.0 (1.7; 2.4)
IV	12 [0.6]	36 [3.1]	51 [3.9]	99 [1.7]	1.6 (1.3; 1.9)
X/NA	76 [4.0]	35 [3.0]	21 [1.6]	132 [2.2]	2.3 (1.9; 2.7)

1.2.2. Cervical cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages 0+	
I	152 [8.0]	75 [6.4]	33 [2.5]	260 [4.4]	4.5 (4.0; 5.1)
II	3 [0.2]	15 [1.3]	8 [0.6]	26 [0.4]	0.4 (0.3; 0.6)
III	6 [0.3]	6 [0.5]	12 [0.9]	24 [0.4]	0.4 (0.2; 0.5)
IV	2 [0.1]	6 [0.5]	4 [0.3]	12 [0.2]	0.2 (0.1; 0.3)
X/NA	74 [3.9]	93 [8.0]	132 [10.1]	299 [5.0]	4.9 (4.3; 5.4)

1.2.3. Cervical cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages 0+	
I	157 [8.3]	81 [7.0]	39 [3.0]	277 [4.6]	4.8 (4.2; 5.4)
II	24 [1.3]	35 [3.0]	36 [2.8]	95 [1.6]	1.6 (1.2; 1.9)
III	35 [1.8]	38 [3.3]	53 [4.1]	126 [2.1]	2.1 (1.7; 2.4)
IV	12 [0.6]	35 [3.0]	51 [3.9]	98 [1.6]	1.6 (1.3; 1.9)
X/NA	9 [0.5]	6 [0.5]	10 [0.8]	25 [0.4]	0.4 (0.2; 0.6)

1.2.4. Cervical cancer incidence by Human Papillomavirus infection: number of new diagnoses, crude and age-standardised incidence rates, 2024

HPV status	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages 0+	
HPV+	140 [7.4]	121 [10.4]	99 [7.6]	360 [6.0]	6.1 (5.5; 6.7)
HPV-	7 [0.4]	11 [0.9]	15 [1.2]	33 [0.6]	0.5 (0.3; 0.7)
Unregistered	19 [1.0]	14 [1.2]	16 [1.2]	49 [0.8]	0.8 (0.6; 1.1)

2. CANCER INCIDENCE TRENDS



2.1. Cervical cancer incidence trends: by region

2.1.1. *Cervical cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	
Belgium	N	629	634	589	688	634	595	603	625	682	635	664	648	646	633	641	610	600	641	648	618	621			
	CR	11.8	11.9	11.0	12.7	11.6	10.8	10.9	11.2	12.1	11.2	11.7	11.4	11.3	11.0	11.1	10.5	10.3	11.0	11.0	10.4	10.4			
	ESR2013	11.9	12.0	11.0	12.8	11.7	11.0	10.9	11.2	12.3	11.4	11.7	11.5	11.5	11.1	11.2	10.6	10.4	11.0	11.1	10.4	10.4	-0.6 (-0.9; -0.3)	2004-2024	
Brussels	N	62	62	78	72	62	74	61	60	67	72	59	54	68	54	60	54	58	41	64	53	43			
	CR	11.9	11.9	14.7	13.5	11.4	13.4	10.8	10.4	11.4	12.1	9.9	9.0	11.2	8.9	9.8	8.8	9.3	6.6	10.3	8.4	6.7			
	ESR2013	12.7	12.6	15.6	14.9	12.4	14.6	11.9	11.0	13.0	13.4	11.1	10.2	12.7	9.7	10.9	10.1	10.3	7.3	11.5	9.6	7.8	-2.4 (-3.3; -1.5)	2004-2024	
Flanders	N	366	389	344	390	362	351	331	326	369	336	339	362	349	363	350	339	330	361	353	349	342			
	CR	12.0	12.7	11.2	12.6	11.6	11.2	10.5	10.2	11.5	10.4	10.4	11.1	10.7	11.0	10.6	10.2	9.9	10.7	10.4	10.2	9.9			
	ESR2013	11.9	12.6	11.0	12.5	11.4	11.1	10.2	10.1	11.5	10.4	10.3	11.1	10.6	10.9	10.4	10.1	9.8	10.6	10.4	10.1	9.7	-0.9 (-1.2; -0.5)	2004-2024	
Wallonia	N	201	183	167	226	210	170	211	239	246	227	266	232	229	216	231	217	212	239	231	216	236			
	CR	11.5	10.5	9.5	12.8	11.8	9.5	11.7	13.2	13.5	12.4	14.5	12.6	12.4	11.7	12.5	11.7	11.4	12.8	12.3	11.5	12.5			
	ESR2013	11.8	10.7	9.6	13.0	12.1	9.6	11.9	13.4	13.7	12.7	14.7	13.0	12.8	11.9	12.6	11.9	11.6	13.0	12.5	11.4	12.7	0.7 (0.0; 1.4)	2004-2024	
																							2.9 (0.4; 5.3)	2004-2011	
																								-0.4 (-1.6; 0.7)	2012-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Cervical cancer incidence trends: by tumour stage

2.2.1. Cervical cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	237	284	272	260	277	0.3 (-0.2; 0.9)	2004-2024
	CR	4.1	4.9	4.6	4.4	4.6		
	ESR2013	4.2	5.0	4.8	4.5	4.8		
II	N	92	85	94	90	95	2.3 (1.4; 3.2)	2004-2024
	CR	1.6	1.5	1.6	1.5	1.6		
	ESR2013	1.6	1.4	1.6	1.5	1.6		
III	N	154	133	153	138	126	2.1 (1.2; 3.0)	2004-2024
	CR	2.6	2.3	2.6	2.3	2.1		
	ESR2013	2.6	2.3	2.6	2.3	2.1		
IV	N	74	106	93	100	98	4.6 (3.6; 5.6)	2004-2024
	CR	1.3	1.8	1.6	1.7	1.6	8.7 (4.7; 12.8)	2004-2010
	ESR2013	1.2	1.7	1.5	1.6	1.6	1.6 (-3.0; 6.4)	2011-2014
							3.4 (1.4; 5.4)	2015-2024
X/NA	N	43	33	36	30	25	-10.8 (-11.6; -10.0)	2004-2024
	CR	0.7	0.6	0.6	0.5	0.4		
	ESR2013	0.7	0.5	0.6	0.5	0.4	-6.8 (-8.3; -5.4)	2004-2015
							-20.8 (-24.1; -17.3)	2016-2019
							-11.0 (-14.7; -7.1)	2020-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Cervical cancer incidence trends: by age group

2.3.1. *Cervical cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024*

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-24 N	2	4	2	6	3	4	4	3	4	4	4	1	3	3	2	1	3	1	3	0	0			
CR	0.3	0.6	0.3	0.9	0.5	0.6	0.6	0.5	0.6	0.6	0.6	0.2	0.5	0.5	0.3	0.2	0.5	0.2	0.5	0.0	0.0			
ESR2013	0.3	0.7	0.3	1.0	0.5	0.6	0.6	0.5	0.6	0.6	0.6	0.2	0.5	0.5	0.3	0.2	0.5	0.2	0.5	0.0	0.0			
25-49 N	300	320	289	320	302	270	283	265	304	276	282	321	271	247	256	235	246	260	265	222	237			
CR	16.2	17.3	15.6	17.3	16.3	14.5	15.2	14.2	16.3	14.8	15.2	17.3	14.6	13.3	13.8	12.6	13.2	14.0	14.2	11.8	12.5			
ESR2013	16.1	17.2	15.5	17.2	16.2	14.5	15.2	14.2	16.4	15.0	15.4	17.5	14.8	13.6	14.1	12.9	13.6	14.4	14.6	12.1	12.9	-1.2 (-1.7; -0.7)	2004-2024	
50-64 N	153	159	150	192	153	160	162	180	184	201	203	162	199	223	204	205	194	205	217	206	195			
CR	16.7	17.1	15.7	19.6	15.2	15.6	15.4	16.8	17.0	18.4	18.4	14.5	17.6	19.6	17.8	17.8	16.8	17.7	18.7	17.7	16.8			
ESR2013	16.8	17.1	15.7	19.4	15.2	15.5	15.4	16.8	17.0	18.4	18.4	14.5	17.6	19.5	17.8	17.8	16.8	17.7	18.6	17.7	16.8	0.4 (-0.2; 1.0)	2004-2024	
65+ N	174	151	148	170	176	161	154	177	190	154	175	164	173	160	179	169	157	175	162	190	189			
CR	16.7	14.3	14.0	16.1	16.6	15.1	14.3	16.3	17.2	13.7	15.4	14.2	14.8	13.5	15.0	13.9	12.8	14.1	12.8	14.8	14.5			
ESR2013	16.4	14.4	13.6	16.2	16.7	15.4	13.8	16.1	17.5	14.2	15.0	14.5	15.5	13.5	15.1	14.2	12.9	14.0	13.1	15.0	14.7	-0.6 (-1.1; 0.0)	2004-2024	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Cervical cancer prevalence: by region

3.1.1. *Cervical cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024*

Region		Females				
		1-year	5-year	10-year	15-year	20-year
Belgium	N	575	2,451	4,355	6,041	7,521
	CR	9.6	40.9	72.6	101	125
	ESR2013	9.6	41.5	73.8	101.9	126.1
Brussels	N	40	198	367	522	665
	CR	6.2	30.9	57.3	81.5	103.8
	ESR2013	7.1	34.9	66.1	94.7	122.3
Flanders	N	314	1,363	2,455	3,380	4,287
	CR	9.1	39.3	70.9	97.5	123.7
	ESR2013	8.9	39.5	71.1	97.2	122.1
Wallonia	N	221	890	1,533	2,139	2,569
	CR	11.7	47.1	81.1	113.2	135.9
	ESR2013	11.9	47.6	82.0	113.9	135.9

4. CANCER SURVIVAL



4.1. Cervical cancer survival: by region

4.1.1. Cervical cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Females						
Belgium	All ages 15+	6,247	88.8% (88.0%; 89.6%)	75.6% (74.4%; 76.8%)	70.4% (69.1%; 71.8%)	66.1% (63.8%; 68.4%)
	15-24	17	N<50	N<50	N<50	N<50
	25-49	2,538	96.7% (95.9%; 97.4%)	88.6% (87.3%; 89.9%)	85.5% (84.1%; 87.0%)	83.1% (81.3%; 85.0%)
	50-64	1,988	91.1% (89.8%; 92.4%)	75.8% (73.8%; 77.8%)	70.0% (67.8%; 72.3%)	64.6% (61.7%; 67.7%)
	65+	1,706	74.3% (72.1%; 76.5%)	55.8% (53.1%; 58.7%)	47.9% (44.7%; 51.3%)	40.9% (34.1%; 49.2%)
Brussels	All ages 15+	537	90.8% (88.2%; 93.5%)	77.6% (73.7%; 81.7%)	69.0% (64.3%; 74.1%)	66.2% (60.4%; 72.4%)
	15-24	4	N<50	N<50	N<50	N<50
	25-49	233	96.2% (93.7%; 98.7%)	85.5% (81.0%; 90.3%)	81.8% (76.7%; 87.3%)	76.8% (70.1%; 84.1%)
	50-64	173	94.0% (90.4%; 97.7%)	80.6% (74.6%; 87.1%)	73.2% (66.0%; 81.1%)	68.6% (59.4%; 79.1%)
	65+	128	76.5% (68.9%; 85.0%)	58.6% (48.9%; 70.2%)	40.1% (29.7%; 54.0%)	41.5% (28.9%; 59.6%)
Flanders	All ages 15+	3,471	89.1% (88.1%; 90.2%)	76.3% (74.8%; 77.9%)	71.7% (69.9%; 73.5%)	66.6% (63.3%; 70.1%)
	15-24	7	N<50	N<50	N<50	N<50
	25-49	1,397	97.1% (96.2%; 98.0%)	89.4% (87.7%; 91.1%)	86.4% (84.4%; 88.3%)	84.7% (82.5%; 87.1%)
	50-64	1,104	92.6% (91.1%; 94.2%)	77.6% (75.1%; 80.3%)	72.2% (69.3%; 75.2%)	66.4% (62.5%; 70.6%)

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	65+	963	73.6% (70.7%; 76.6%)	55.5% (52.0%; 59.3%)	49.1% (45.0%; 53.5%)	38.5% (29.4%; 50.4%)
Wallonia	All ages 15+	2,240	87.8% (86.4%; 89.2%)	74.0% (72.0%; 76.0%)	68.9% (66.6%; 71.3%)	65.2% (61.7%; 68.9%)
	15-24	6	N<50	N<50	N<50	N<50
	25-49	909	96.1% (94.9%; 97.4%)	88.1% (85.9%; 90.3%)	85.2% (82.8%; 87.8%)	82.2% (79.1%; 85.4%)
	50-64	711	88.1% (85.7%; 90.5%)	71.8% (68.4%; 75.3%)	65.8% (62.0%; 69.9%)	60.6% (55.8%; 65.9%)
	65+	615	74.9% (71.2%; 78.7%)	55.6% (51.1%; 60.5%)	47.8% (42.5%; 53.8%)	44.3% (34.0%; 57.8%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2. Cervical cancer survival: by tumour stage

4.2.1. Cervical cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
All	6,247	88.8% (88.0%; 89.6%)	80.0% (79.0%; 81.1%)	75.6% (74.4%; 76.8%)	72.7% (71.4%; 74.0%)	70.4% (69.1%; 71.8%)	66.1% (63.8%; 68.4%)
I	1,375	98.6% (97.9%; 99.4%)	95.9% (94.6%; 97.1%)	94.4% (92.9%; 95.9%)	92.1% (90.3%; 94.0%)	91.0% (88.9%; 93.1%)	83.5% (76.2%; 91.6%)
II	871	93.8% (92.0%; 95.6%)	86.6% (84.0%; 89.2%)	81.4% (78.4%; 84.6%)	76.4% (72.9%; 80.0%)	73.5% (69.7%; 77.6%)	64.2% (56.8%; 72.7%)
III	1,209	88.1% (86.2%; 90.1%)	75.8% (73.3%; 78.4%)	68.6% (65.8%; 71.5%)	65.0% (62.0%; 68.1%)	62.5% (59.4%; 65.8%)	57.5% (53.2%; 62.1%)
IV	837	59.2% (55.9%; 62.7%)	36.5% (33.3%; 40.1%)	26.9% (23.8%; 30.3%)	23.3% (20.3%; 26.8%)	19.5% (16.5%; 23.0%)	12.3% (8.9%; 17.2%)
X/NA	1,968	92.7% (91.4%; 93.9%)	87.0% (85.4%; 88.6%)	84.5% (82.7%; 86.3%)	82.7% (80.7%; 84.6%)	80.6% (78.4%; 82.8%)	79.4% (76.3%; 82.7%)

4.2.2. Cervical cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
All	6,247	88.8% (88.0%; 89.6%)	80.0% (79.0%; 81.1%)	75.6% (74.4%; 76.8%)	72.7% (71.4%; 74.0%)	70.4% (69.1%; 71.8%)	66.1% (63.8%; 68.4%)
I	2,486	99.7% (99.3%; 100.0%)	98.3% (97.7%; 99.0%)	97.1% (96.2%; 97.9%)	95.7% (94.6%; 96.8%)	94.6% (93.4%; 95.9%)	91.9% (89.1%; 94.7%)
II	268	93.4% (90.3%; 96.7%)	82.6% (77.8%; 87.8%)	80.9% (75.8%; 86.4%)	75.8% (70.0%; 82.0%)	71.5% (65.2%; 78.3%)	64.0% (53.4%; 76.7%)
III	375	95.9% (93.7%; 98.1%)	85.5% (81.8%; 89.3%)	80.0% (75.7%; 84.5%)	76.3% (71.7%; 81.2%)	72.3% (67.1%; 77.8%)	68.3% (62.1%; 75.1%)
IV	155	61.2% (53.9%; 69.4%)	35.2% (28.3%; 43.6%)	28.2% (21.8%; 36.5%)	23.6% (17.6%; 31.8%)	20.9% (15.0%; 29.1%)	11.4% (6.2%; 21.0%)
X/NA	2,972	79.8% (78.3%; 81.4%)	66.1% (64.3%; 68.0%)	59.0% (57.1%; 61.0%)	55.2% (53.2%; 57.3%)	52.4% (50.3%; 54.6%)	47.0% (43.1%; 51.2%)

4.2.3. Cervical cancer survival by stage: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
All	6,247	88.8% (88.0%; 89.6%)	80.0% (79.0%; 81.1%)	75.6% (74.4%; 76.8%)	72.7% (71.4%; 74.0%)	70.4% (69.1%; 71.8%)	66.1% (63.8%; 68.4%)
I	2,622	99.1% (98.6%; 99.6%)	97.3% (96.5%; 98.0%)	95.8% (94.8%; 96.7%)	94.2% (93.1%; 95.4%)	93.0% (91.7%; 94.4%)	89.4% (85.8%; 93.2%)
II	907	93.5% (91.7%; 95.3%)	85.9% (83.4%; 88.5%)	81.6% (78.7%; 84.7%)	76.4% (73.0%; 80.0%)	73.7% (69.9%; 77.6%)	64.2% (57.0%; 72.3%)
III	1,345	89.4% (87.7%; 91.2%)	77.9% (75.6%; 80.3%)	71.1% (68.5%; 73.8%)	67.9% (65.2%; 70.8%)	64.9% (61.9%; 68.0%)	59.8% (55.9%; 64.0%)
IV	871	59.0% (55.7%; 62.4%)	36.6% (33.4%; 40.1%)	27.2% (24.2%; 30.5%)	23.3% (20.4%; 26.6%)	19.7% (16.8%; 23.1%)	12.7% (9.4%; 17.2%)
X/NA	515	76.9% (73.2%; 80.8%)	60.7% (56.4%; 65.4%)	55.1% (50.5%; 60.0%)	51.7% (47.0%; 56.9%)	49.0% (44.0%; 54.6%)	49.9% (44.0%; 56.6%)

5. CANCER SURVIVAL TRENDS



5.1. Cervical cancer survival trends: by tumour stage

5.1.1. *Cervical cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024*

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	3,742	87.9% (86.9%; 89.1%)	73.9% (72.4%; 75.4%)	69.0% (67.4%; 70.7%)
	I	1,435	99.0% (98.3%; 99.6%)	94.2% (92.7%; 95.6%)	91.6% (89.9%; 93.4%)
	II	351	91.1% (87.8%; 94.5%)	72.6% (67.5%; 78.1%)	62.6% (56.8%; 69.0%)
	III	565	86.5% (83.6%; 89.5%)	60.2% (56.0%; 64.6%)	53.0% (48.7%; 57.7%)
	IV	276	53.5% (47.9%; 59.9%)	23.4% (18.7%; 29.1%)	16.5% (12.5%; 21.9%)
	X/NA	1,115	82.0% (79.6%; 84.4%)	67.6% (64.7%; 70.6%)	62.9% (59.9%; 66.1%)
2010-2014	All	3,189	86.7% (85.5%; 88.0%)	73.1% (71.4%; 74.7%)	68.1% (66.3%; 70.0%)
	I	1,286	98.6% (97.9%; 99.4%)	94.7% (93.3%; 96.2%)	92.7% (90.9%; 94.5%)
	II	367	94.6% (91.9%; 97.3%)	73.2% (68.4%; 78.5%)	66.6% (61.2%; 72.5%)
	III	551	88.2% (85.4%; 91.1%)	66.3% (62.3%; 70.6%)	56.4% (52.1%; 61.0%)
	IV	315	50.5% (45.2%; 56.5%)	29.1% (24.3%; 34.8%)	25.7% (21.0%; 31.4%)
	X/NA	677	75.3% (72.0%; 78.8%)	57.7% (53.8%; 61.9%)	51.6% (47.4%; 56.1%)
2015-2019	All	3,150	88.3% (87.1%; 89.5%)	73.9% (72.3%; 75.6%)	68.5% (66.7%; 70.3%)
	I	1,297	99.2% (98.5%; 99.8%)	94.8% (93.4%; 96.2%)	91.7% (89.9%; 93.5%)
	II	453	92.9% (90.3%; 95.5%)	81.8% (77.8%; 86.0%)	74.2% (69.4%; 79.3%)
	III	643	88.9% (86.4%; 91.5%)	67.4% (63.6%; 71.4%)	59.8% (55.7%; 64.1%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	404	55.8% (51.1%; 61.0%)	24.2% (20.2%; 28.8%)	17.3% (13.8%; 21.7%)
	X/NA	358	78.3% (74.0%; 82.9%)	56.2% (50.8%; 62.1%)	50.7% (44.9%; 57.3%)
2020-2024	All	3,100	89.3% (88.2%; 90.5%)	77.3% (75.6%; 79.0%)	72.7% (70.6%; 74.9%)
	I	1,325	99.0% (98.3%; 99.7%)	96.7% (95.3%; 98.1%)	94.7% (92.4%; 96.9%)
	II	454	93.9% (91.5%; 96.4%)	81.4% (77.0%; 86.0%)	72.0% (65.9%; 78.7%)
	III	702	89.8% (87.5%; 92.2%)	75.1% (71.5%; 78.8%)	71.8% (67.6%; 76.2%)
	IV	467	61.7% (57.3%; 66.4%)	29.3% (25.0%; 34.4%)	21.5% (16.9%; 27.2%)
	X/NA	157	73.7% (66.7%; 81.3%)	52.9% (44.9%; 62.3%)	43.5% (34.5%; 54.8%)

6. CANCER MORTALITY



6.1. Cervical cancer mortality: by region

6.1.1. *Cervical cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Belgium	0	0	0	0	0	0	3	2	7	11	11	14	12	10	13	21	10	10	11	0	135	2.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.5]	[1.8]	[3.0]	[2.8]	[3.5]	[3.1]	[3.0]	[4.4]	[8.5]	[5.7]	[7.5]	[15.5]	[0.0]	[2.3]	(1.8; 2.5)
Brussels	0	0	0	0	0	0	0	1	0	0	1	3	1	1	1	0	1	2	0	0	11	2.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[0.0]	[0.0]	[2.6]	[8.8]	[3.3]	[4.0]	[4.7]	[0.0]	[7.8]	[20.4]	[0.0]	[0.0]	[1.7]	(0.8; 3.3)
Flanders	0	0	0	0	0	0	2	1	7	8	8	9	6	6	6	14	7	7	9	0	90	2.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.5]	[3.2]	[3.8]	[3.6]	[3.8]	[2.6]	[3.0]	[3.4]	[9.3]	[6.4]	[8.2]	[20.5]	[0.0]	[2.6]	(1.9; 2.9)
Wallonia	0	0	0	0	0	0	1	0	0	3	2	2	5	3	6	7	2	1	2	0	34	1.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[2.5]	[1.6]	[1.6]	[4.1]	[2.7]	[6.0]	[9.0]	[3.9]	[2.6]	[9.4]	[0.0]	[1.8]	(1.1; 2.3)

7. CANCER MORTALITY TRENDS



7.1. Cervical cancer mortality trends: by region

7.1.1. Cervical cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	186	168	162	158	184	193	163	197	179	176	157	161	145	170	175	143	144	164	145	135	-2.1 (-2.8; -1.4)	2004-2023
	CR	3.5	3.1	3.0	2.9	3.4	3.5	2.9	3.5	3.2	3.1	2.8	2.8	2.5	3.0	3.0	2.5	2.5	2.8	2.5	2.3		
	ESR2013	3.5	3.2	3.0	3.0	3.3	3.5	3.0	3.4	3.1	3.1	2.7	2.7	2.4	2.9	2.9	2.3	2.3	2.6	2.3	2.1		
Brussels	N	22	9	16	15	15	26	12	24	11	15	10	12	13	16	17	6	14	7	10	11	-4.1 (-6.9; -1.1)	2004-2023
	CR	4.2	1.7	3.0	2.8	2.8	4.7	2.1	4.2	1.9	2.5	1.7	2.0	2.1	2.6	2.8	1.0	2.3	1.1	1.6	1.7		
	ESR2013	4.7	1.8	3.3	3.3	2.9	5.6	2.5	4.6	2.3	3.2	1.8	2.5	2.5	2.9	3.2	1.0	2.6	1.1	1.7	2.1		
Flanders	N	126	116	109	102	128	119	110	120	129	107	103	93	86	105	106	87	91	111	103	90	-2.5 (-3.3; -1.7)	2004-2023
	CR	4.1	3.8	3.5	3.3	4.1	3.8	3.5	3.8	4.0	3.3	3.2	2.9	2.6	3.2	3.2	2.6	2.7	3.3	3.0	2.6		
	ESR2013	4.2	3.8	3.5	3.3	4.0	3.7	3.4	3.5	3.7	3.2	3.0	2.6	2.4	3.0	2.9	2.4	2.4	3.0	2.8	2.4		
Wallonia	N	38	43	37	41	41	48	41	53	39	54	44	56	46	49	52	50	39	46	32	34	-1.0 (-2.0; 0.0) 2.5 (0.5; 4.4) -5.5 (-8.0; -2.9)	2004-2023 2004-2015 2016-2023
	CR	2.2	2.5	2.1	2.3	2.3	2.7	2.3	2.9	2.1	3.0	2.4	3.0	2.5	2.6	2.8	2.7	2.1	2.5	1.7	1.8		
	ESR2013	2.1	2.6	2.1	2.4	2.3	2.7	2.4	2.9	2.1	2.9	2.3	3.1	2.5	2.7	2.7	2.6	2.0	2.4	1.7	1.7		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

8. CARCINOMA IN SITU INCIDENCE



8.1. Cervical carcinoma in situ incidence: by region

8.1.1. *Cervical carcinoma in situ incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024*

N [CR]																					ESR2013 (95%CI)	
Region	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Females																						
Belgium	0	0	0	5	186	996	1,183	1,265	1,111	795	518	350	198	111	53	21	7	3	1	0	6,803	
	[0.0]	[0.0]	[0.0]	[1.5]	[55.3]	[275.4]	[302.1]	[329.4]	[287.7]	[215.0]	[134.4]	[89.1]	[51.3]	[32.2]	[17.8]	[8.2]	[4.0]	[2.2]	[1.4]	[0.0]	[114.0]	
Brussels	0	0	0	1	13	140	117	125	73	52	26	25	13	9	3	3	0	0	0	0	600	
	[0.0]	[0.0]	[0.0]	[2.7]	[30.1]	[246.9]	[214.3]	[256.7]	[160.4]	[124.2]	[67.5]	[72.7]	[42.5]	[35.8]	[13.9]	[16.2]	[0.0]	[0.0]	[0.0]	[0.0]	[94.1]	
Flanders	0	0	0	4	128	646	755	795	706	496	359	216	120	64	32	10	6	2	1	0	4,340	
	[0.0]	[0.0]	[0.0]	[2.1]	[69.7]	[325.5]	[345.5]	[369.5]	[317.4]	[235.1]	[162.1]	[92.6]	[51.8]	[31.0]	[18.1]	[6.5]	[5.5]	[2.3]	[2.2]	[0.0]	[126.0]	
Wallonia	0	0	0	0	45	210	311	345	332	247	133	109	65	38	18	8	1	1	0	0	1,863	
	[0.0]	[0.0]	[0.0]	[0.0]	[41.0]	[197.1]	[262.6]	[287.0]	[280.7]	[211.2]	[106.0]	[87.1]	[52.6]	[33.6]	[18.0]	[9.7]	[1.9]	[2.6]	[0.0]	[0.0]	[98.8]	

9. CARCINOMA IN SITU INCIDENCE TRENDS



9.1. Cervical carcinoma in situ incidence trends: by region

9.1.1. *Cervical carcinoma in situ incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024*

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium N	1,794	1,703	1,895	2,160	2,420	2,509	2,648	3,210	3,891	3,741	4,389	4,751	5,099	6,181	6,312	6,939	5,986	6,489	6,411	6,705	6,803		
CR	33.8	31.9	35.3	40.0	44.5	45.7	47.9	57.5	69.2	66.2	77.3	83.3	89.0	107.4	109.2	119.6	102.6	111.0	109.1	113.0	114.0		
ESR2013	32.9	31.4	34.9	39.8	44.3	45.8	48.2	58.1	70.1	67.2	78.8	85.2	91.4	110.7	112.6	123.5	106.7	115.6	113.8	117.7	119.2	7.3 (6.8; 7.8)	2004-2024
																						10.4 (9.6; 11.2)	2004-2017
																						1.8 (0.3; 3.3)	2018-2024
Brussels N	289	264	277	347	372	294	394	424	563	499	538	501	582	665	593	703	565	641	588	624	600		
CR	55.6	50.5	52.4	64.9	68.6	53.2	70.0	73.5	96.1	84.2	90.1	83.2	95.7	109.2	96.9	114.1	91.0	103.2	94.5	98.6	94.1		
ESR2013	50.5	45.0	48.0	58.2	61.4	47.7	62.3	64.3	83.9	73.3	78.7	73.3	84.0	95.3	84.6	99.8	81.4	91.6	83.9	86.6	83.9	3.4 (2.6; 4.2)	2004-2024
																						5.7 (4.1; 7.3)	2004-2015
																						0.6 (-1.3; 2.5)	2016-2024
Flanders N	1,019	967	1,067	1,409	1,562	1,604	1,597	1,885	2,187	2,064	2,516	2,592	2,873	3,581	3,904	4,151	3,704	3,947	4,008	4,155	4,340		
CR	33.4	31.6	34.6	45.4	50.0	51.0	50.4	59.0	68.0	63.9	77.5	79.5	87.7	108.7	117.9	124.7	110.6	117.5	118.5	121.4	126.0		
ESR2013	32.5	31.0	34.3	45.4	50.2	51.7	51.4	60.5	70.0	66.0	80.5	83.0	91.8	114.1	124.0	131.4	117.4	124.8	126.1	129.1	134.4	7.7 (7.1; 8.4)	2004-2024
																						10.3 (9.3; 11.3)	2004-2017
																						3.2 (1.2; 5.1)	2018-2024

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Wallonia N	486	472	551	404	486	611	657	901	1,141	1,178	1,335	1,658	1,644	1,935	1,815	2,085	1,717	1,901	1,815	1,926	1,863		
CR	27.9	27.0	31.4	22.8	27.3	34.2	36.5	49.7	62.7	64.4	72.8	90.1	89.1	104.6	97.9	112.2	92.1	102.0	97.0	102.4	98.8		
ESR2013	27.8	27.2	31.7	23.2	27.9	35.1	37.7	51.5	65.1	67.1	76.0	94.3	93.6	110.4	103.1	118.6	97.9	108.6	103.2	108.7	105.3	8.3 (7.1; 9.5)	2004-2024
																						13.1 (11.2; 15.1)	2004-2017
																						-0.2 (-3.6; 3.4)	2018-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

9.2. Cervical carcinoma in situ incidence trends: by age group

9.2.1. Cervical carcinoma in situ incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-24	N	143	128	130	168	203	223	235	288	319	300	298	275	267	323	309	313	272	267	240	238	191			
	CR	23.1	20.6	20.8	26.6	31.8	34.6	36.3	44.1	48.6	45.7	45.6	42.3	41.2	50.3	48.5	49.3	42.6	41.7	37.1	36.1	28.5			
	ESR2013	23.3	20.9	21.3	27.5	33.0	35.6	37.1	44.5	48.5	45.2	45.0	41.8	41.1	50.4	48.7	49.7	43.0	42.2	37.8	37.1	29.6	2.8 (1.8; 3.7)		2004-2024
																							10.9 (8.1; 13.8)		2004-2012
																							0.8 (-3.7; 5.5)		2013-2016
																							-3.9 (-6.3; -1.4)		2017-2024
25-49	N	1,462	1,406	1,569	1,741	1,966	2,025	2,108	2,581	3,182	3,014	3,624	3,904	4,200	5,040	5,174	5,627	4,854	5,226	5,107	5,226	5,350			
	CR	79.0	76.0	84.7	93.9	105.9	109.0	113.4	138.6	170.9	162.0	195.3	211.0	226.8	272.1	278.8	302.7	260.8	280.9	274.1	277.4	282.6			
	ESR2013	78.8	76.2	85.1	94.6	106.5	109.8	114.2	139.3	171.5	162.2	195.1	210.2	225.9	270.9	276.8	300.7	259.5	279.8	272.7	275.8	281.8	7.2 (6.7; 7.8)		2004-2024
																							10.7 (9.8; 11.5)		2004-2017
																							1.2 (-0.4; 2.8)		2018-2024
50-64	N	141	135	153	212	196	206	253	271	329	352	405	476	522	712	710	848	734	859	887	1,081	1,066			
	CR	15.4	14.5	16.0	21.6	19.5	20.0	24.1	25.3	30.4	32.2	36.7	42.5	46.2	62.4	61.9	73.6	63.5	74.1	76.3	92.6	91.6			
	ESR2013	15.0	14.1	15.8	21.4	19.4	19.9	24.0	25.2	30.2	32.0	36.6	42.4	46.1	62.6	62.3	74.4	64.8	75.5	78.3	94.6	93.7	10.7 (9.9; 11.6)		2004-2024
65+	N	48	34	43	39	55	55	52	70	61	75	62	96	110	106	119	151	126	137	177	160	196			
	CR	4.6	3.2	4.1	3.7	5.2	5.2	4.8	6.4	5.5	6.7	5.5	8.3	9.4	9.0	9.9	12.5	10.2	11.0	14.0	12.5	15.0			
	ESR2013	4.7	3.5	4.3	3.9	5.5	5.4	5.3	6.9	5.8	7.1	5.9	8.8	10.2	9.7	10.7	13.3	11.2	11.9	14.9	13.3	16.1	7.6 (6.6; 8.6)		2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026